checkAd
    Startseite > Aktien > Bristol-Myers Squibb > Nachrichten
    Bristol-Myers Squibb Aktie
    37,42
     
    EUR
    +0,29 %
    +0,11 EUR
    Letzter Kurs 12:13:40 Tradegate
    37,31
     
    EUR
    300 STK
    Geldkurs 12:13:40
    37,42
     
    EUR
    300 STK
    Briefkurs 12:13:40
    ISIN: US1101221083 · WKN: 850501 · SYM: BRM · USA ·

    Neueste Nachrichten

    ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
    28.05.24 · Accesswire · Bristol-Myers Squibb
    Tagesvorschau: Die Handelstermine am 28. Mai
    27.05.24 · BörsenNEWS.de · Bristol-Myers Squibb
    Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
    23.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
    23.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
    22.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
    22.05.24 · PR Newswire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
    21.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
    21.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
    16.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
    16.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
    10.05.24 · Business Wire (engl.) · Bristol-Myers Squibb
    Bristol Myers Squibb to Participate in Upcoming Investor Conferences
    07.05.24 · Business Wire (engl.) · Bristol-Myers Squibb